Key Points
- Director William Carson purchased 8,000 shares of Annexon on April 10 at $6.20 per share under a pre-arranged Rule 10b5-1 plan, raising his holding to 70,405 shares (a 12.82% increase), per an SEC filing.
- Analysts lean positive: MarketBeat shows a consensus rating of "Moderate Buy" with an average price target of $17.00 (five Buys, one Hold, one Sell).
- Annexon beat quarterly EPS expectations (reported -$0.28 vs. -$0.32) and is advancing its lead asset ANX005 in Phase 2 trials for Guillain-Barré syndrome and other neuro indications; the stock trades near $5.80 with a market cap around $931M.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson acquired 8,000 shares of the business's stock in a transaction dated Friday, April 10th. The stock was purchased at an average price of $6.20 per share, with a total value of $49,600.00. Following the completion of the acquisition, the director directly owned 70,405 shares in the company, valued at approximately $436,511. This represents a 12.82% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Annexon Trading Down 0.2%
ANNX opened at $5.80 on Wednesday. The stock has a 50-day moving average price of $5.45 and a 200-day moving average price of $4.77. Annexon, Inc. has a 12-month low of $1.40 and a 12-month high of $7.18. The stock has a market capitalization of $930.73 million, a P/E ratio of -4.26 and a beta of 1.14.
Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.04. On average, equities research analysts predict that Annexon, Inc. will post -0.96 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC raised its position in Annexon by 13.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company's stock valued at $100,000 after purchasing an additional 2,348 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Annexon by 65.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company's stock valued at $35,000 after purchasing an additional 2,785 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its position in Annexon by 0.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company's stock valued at $1,790,000 after purchasing an additional 2,875 shares during the last quarter. ProShare Advisors LLC raised its position in Annexon by 21.7% during the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company's stock valued at $124,000 after purchasing an additional 4,410 shares during the last quarter. Finally, Citizens Financial Group Inc. RI raised its position in shares of Annexon by 14.3% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company's stock worth $122,000 after acquiring an additional 5,000 shares in the last quarter.
Analyst Upgrades and Downgrades
ANNX has been the subject of a number of research reports. Chardan Capital reiterated a "buy" rating and issued a $16.00 price objective on shares of Annexon in a report on Friday, March 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Annexon in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a report on Wednesday, January 14th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Annexon presently has an average rating of "Moderate Buy" and a consensus price target of $17.00.
Get Our Latest Research Report on Annexon
Annexon Company Profile
(
Get Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
